Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Porfimer Sodium I-PDT in Head and Neck Cancer
NCT03727061Phase 1Terminated
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Jul 2019
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of porfimer sodium in head and neck cancer (HNC), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Frequency of Adverse Events Per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 up to 30 days and Recommended light irradiance dose for a future Phase 2 trial. Started Jul 2019; status: terminated.
02
Drugs
porfimer sodium
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT03727061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03727061.